944351-60-4

Upstream product

• 1130-21-8 ethyl 1-cyanocyclohexane-1-carboxylate 
• 1309660-35-2 potassium 1-cyanocyclohexanecarboxylate 
• 146397-87-7 p-(trifluoromethyl)phenyl trifluoromethanesulfonate 
• 111-24-0 1,5-dibromo-pentane 
• 2338-75-2 4-(Trifluoromethyl)phenylacetonitrile 

Downstream Products

• 944348-11-2 (1-(4-(trifluoromethyl)phenyl)cyclohexyl)methanamine 
• 1260786-37-5 C₁₄H₁₅F₃O₂ 
• 944351-61-5 1-(4-(trifluoromethyl)phenyl)cyclohexane-1-carbaldehyde 

Relevant academic research and scientific papers

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Synthesis of α-Aryl nitriles through palladium-catalyzed decarboxylative coupling of cyanoacetate salts with aryl halides and triflates

Worth its salt: The palladium-catalyzed decarboxylative coupling of the cyanoacetate salt as well as its mono- and disubstituted derivatives with aryl chlorides, bromides, and triflates is described (see scheme). This reaction is potentially useful for the preparation of a diverse array of α-aryl nitriles and has good functional group tolerance. S-Phos=2-(2,6- dimethoxybiphenyl)dicyclohexylphosphine), Xant-Phos=4,5-bis(diphenylphosphino)- 9,9-dimethylxanthene. Copyright

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants.

CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.